Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that data from more than 25 Signatera studies will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 - June 3, 2025 in Chicago, IL.
Together with its collaborators, Natera will showcase the clinical utility of Signatera across 10 different cancer types. This extraordinary breadth of data includes analyses of thousands of patients, demonstrating Natera's leadership in circulating tumor DNA (ctDNA) monitoring and molecular residual disease (MRD) assessment.
'The depth and breadth of Natera's research at ASCO is our most significant to date, with multiple impactful datasets in several histologies,' said Alexey Aleshin, M.D., corporate chief medical officer and general manager of oncology at Natera. 'The interim analysis from the DARE trial shows a possible first signal in a randomized setting that treating high-risk breast cancer patients based on Signatera results can impact clearance rates. We also look forward to sharing results on our ultra-sensitive Signatera Genome assay, along with numerous other presentations underscoring our commitment to advance the way cancer is managed.'
Highlights include:
DARE Clinical Trial: Oral Presentation
DARE is a prospective, randomized study, launched in 2021, to investigate the utility of Signatera for guiding adjuvant endocrine therapy in 585 women with high-risk, estrogen receptor-positive, HER2-negative (ER+/HER2-) breast cancer. It assesses the novel concept of 'treatment on molecular recurrence' (TOMR). Patients who were Signatera-positive and imaging-negative were randomized into two arms: the standard-of-care (SOC) arm with endocrine therapy vs. the escalated arm with fulvestrant+palbociclib (CDK 4/6i). This interim analysis of 507 women and 2,208 plasma samples demonstrates the exceptional clinical performance of Signatera, and the early feasibility of both this treatment escalation approach and the TOMR trial strategy, including:
Strong test sensitivity and NPV: Among patients who remained persistently Signatera-negative during screening (>400 pts), 99% remained recurrence free with a median follow up of 27.4 months.
High randomization rate: Of patients who tested Signatera-positive, 73% were negative on imaging, and 93% were willing to be randomized.
2x higher ctDNA clearance: Patients in Arm A had a 2x higher rate of ctDNA clearance at 3 months vs. Arm B.
Signatera Monitoring in Metastatic Breast Cancer: Oral Presentation
This real-world analysis of over 600 metastatic breast cancer (mBC) patients across all disease subtypes and a wide range of therapeutic regimens (e.g., chemo, ADCs, CDK4/6) shows the utility of metastatic monitoring with Signatera:
Serial ctDNA testing done at an appropriate cadence (6 weeks) can inform treatment response and clinical decisions in metastatic breast cancer.
Signatera ctDNA dynamics were the strongest predictor of treatment benefit in a multivariate analysis, based on measuring time to next treatment (TTNT).
Nearly 75% of patients with favorable dynamics remained on the same treatment for over 4 months, including those receiving antibody drug conjugates (ADCs) where therapy response can be challenging to evaluate on imaging.
Pan-Cancer Performance of Signatera Genome: Poster Presentation
Large-scale presentation of Signatera's Genome assay, analyzing more than 3,000 samples from over 300 patients across 5 major cancer types.
The study includes analysis of patients with breast cancer, colorectal cancer, non-small cell lung cancer, melanoma, and renal cell carcinoma.
Signatera Performance in Post-Surgical Stage I-IIIb Melanoma: Poster Presentation
This study includes 197 patients and 1,681 plasma samples, tested for a median period of 2 years. This is one of the most comprehensive MRD/monitoring datasets thus far in early melanoma, demonstrating the ability of Signatera to identify patients who may benefit from escalated imaging or earlier treatment initiation.
Post-surgical Signatera-positivity was the most significant predictor of recurrence free survival (RFS).
In the surveillance setting, Signatera-positivity was predictive of shorter RFS (HR: 24.0, P < 0.001).
Full list of oral presentations at ASCO:
May 30, 2:45 PM CT | 3008 | Breast
Presenter: Silver Alkhafaji
Circulating tumor DNA (ctDNA) in patients with stage 2/3 HR+HER2-negative breast cancer (BC) treated with neoadjuvant endocrine therapy (NET) in the I-SPY2 endocrine optimization pilot (EOP) trial
June 1, 9:45 AM CT | 4503 | Genitourinary
Presenter: Thomas Powles, MBBS, MRCP, M.D.
Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA
June 1, 11:30 AM CT | 3518 | Gastrointestinal
Presenter: Aron Bercz, M.D.
Circulating Tumor DNA Provides an Early Response Assessment in Anal Squamous Cell Carcinoma Treated With Definitive Chemoradiation
June 1, 4:30 PM CT | 1010 | Breast
Presenter: Lajos Pusztai, M.D., DPhil
Circulating tumor (ct)DNA monitoring of ER+/HER2- high-risk breast cancer (BC) during adjuvant endocrine therapy (ET) (DARE)
June 1, 4:30 PM CT | 1011 | Breast
Presenter: Pedram Razavi, M.D., Ph.D.
Circulating tumor DNA (ctDNA) dynamics as a predictor of treatment response in metastatic breast cancer (mBC)
June 2, 3:00 PM CT | 504 | Breast
Presenter: Rita Mukhtar, M.D.
Predicting nodal burden after neoadjuvant chemotherapy (NAC) with circulating tumor (ct)DNA for surgical planning: Results from the I-SPY2 trial
Full list of poster presentations at ASCO:
May 31, 9:00 AM CT | 11537 | Sarcoma
Presenter: Adie Victor, M.D., M.S.
Early on-treatment circulating tumor (ct)DNA dynamics in response to therapy in patients with sarcoma
May 31, 9:00 AM CT | 11531 | Sarcoma
Presenter: Maggie Zhou, M.D.
Early assessment of response to chemotherapy via ctDNA in soft tissue sarcoma
May 31, 9:00 AM CT | TPS3647 | Gastrointestinal
Presenter: Clara Montagut, M.D.
A precision medicine trial leveraging tissue and blood-based tumor genomics to optimize treatment in resected stage III and high-risk stage II colon cancer (CC) patients (pts): The SAGITTARIUS Trial.
May 31, 9:00 AM CT | 4067 | Gastrointestinal - FMI
Presenter: Michele Prisciandaro, M.D.
Tumor-informed liquid biopsy in predicting recurrence in patients with operable gastroesophageal adenocarcinoma: the LIQUID study
May 31, 9:00 AM CT | 4130 | Gastrointestinal
Presenter: Maen Abdelrahim, M.D.
Real-world analysis of ctDNA and other biomarkers in patients with curatively resected Stage I-III Biliary Tract Cancer
May 31, 9:00 AM CT | 3600 | Gastrointestinal
Presenter: Eiji Oki, Ph.D.
Impact of Perioperative Complications on ctDNA-based MRD Detection and Prognosis: Insights from the GALAXY Study
May 31, 9:00 AM CT | 3591 | Gastrointestinal
Presenter: Emerik Osterlund, M.D., Ph.D.
Biologic correlates of circulating tumor DNA (ctDNA) shedding in the INTERCEPT colorectal cancer (CRC) study
May 31, 9:00 AM CT | 3597 | Colorectal
Presenter: Midhun Malla, M.D., M.S.
ctDNA dynamics and targeted therapies associated with genetic mutations in patients with colorectal cancer
May 31, 9:00 AM CT | 4073 | Esophagogastric Gastric
Presenter: Reetu Mukherji, M.D.
Exome analysis of over 5000 esophagogastric cancers
June 1, 9:00 AM CT | 9574 | Merkel Cell Carcinoma
Presenter: Joshua Elbridge Chan
Comparison of surveillance circulating tumor DNA and merkel polyomavirus antibody titer for detection of merkel cell carcinoma recurrence
June 1, 9:00 AM CT | 9571 | Melanoma
Presenter: George Ansstas, M.D.
Longitudinal ctDNA monitoring for post-surgical molecular residual disease in patients with stage I-IIIb melanoma
June 1, 9:00 AM CT | 9523 | Melanoma
Presenter: Caroline Burkey
Circulating tumor DNA (ctDNA) dynamics during anti-PD-1 based therapy to predict clinical outcomes in advanced stage melanoma: A multicenter retrospective study.
June 1, 9:00 AM CT | 9584 | Melanoma
Presenter: Vincent The-Luc Ma
Sensitivity of circulating tumor DNA (ctDNA) for disease recurrence or relapse in melanoma patients
June 1, 9:00 AM CT | 5563 | Gynecological
Presenter: Jung-Yun Lee, M.D., Ph.D.
ctDNA monitoring in participants with ovarian cancer treated with neoadjuvant pembrolizumab (pembro) plus chemotherapy (chemo) with or without the anti–immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830
June 2, 9:00 AM CT | 4565 | Genitourinary
Presenter: Adanma Ayanambakkam, M.D.
Association of Tumor-Informed ctDNA-based Molecular Residual Disease (MRD) with Clinical Outcomes for Upper Tract Urothelial Cancer (UTUC)
June 2, 9:00 AM CT | 4602 | Genitourinary
Presenter: Ilana Epstein
Correlation of circulating tumor DNA (ctDNA) dynamics with clinical response in muscle-invasive bladder cancer (MIBC) patients (pts) undergoing trimodality therapy (TMT)
June 2, 9:00 AM CT | 4560 | Genitourinary
Presenter: Kevin R. Reyes, BS
Circulating tumor DNA (ctDNA) monitoring in patients (pts) with advanced urothelial carcinoma (aUC) treated with Enfortumab Vedotin +/- Pembrolizumab (EVP)
June 2, 9:00 AM CT | TPS620 | Breast
Presenter: Michail Ignatiadis, M.D., Ph.D.
EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)
June 2, 9:00 AM CT | 581 | Breast
Presenter: Julia Foldi, M.D., Ph.D.
Serial circulating tumor DNA (ctDNA) monitoring in early-stage, HR+/HER2-, invasive lobular carcinoma (ILC) of the breast and impact on clinical outcomes
June 2, 9:00 AM CT | 560 | Breast
Presenter: Marla Lipsyc-Sharf, M.D.
Cadence of circulating tumor DNA (ctDNA) testing for molecular surveillance in early-stage breast cancer (eBC)
June 2, 9:00 AM CT | 612 | Breast
Presenter: Mei Wei, M.D.
I-SPY2 endocrine optimization pilot (EOP): Neoadjuvant lasofoxifene (Laso) in molecularly selected patients with hormone receptor positive (HR+)/HER2 negative (HER2-) stage 2/3 breast cancer (BC)
June 2, 1:30 PM CT | 3142 | Pancancer
Presenter: Mridula George, M.D.
Clinical performance of Signatera Genome assay in a cohort of patients (pts) with solid tumors
June 2, 1:30 PM CT | 3048 | Gastrointestinal
Presenter: John Paul Y.C. Shen, M.D.
Development of a methylation-based, tissue-free test for the detection of molecular residual disease by circulating tumor DNA
About Signatera
Signatera is a personalized, tumor-informed, molecular residual disease test for patients previously diagnosed with cancer. Custom-built for each individual, Signatera uses circulating tumor DNA to detect and quantify cancer left in the body, identify recurrence earlier than standard of care tools, and help optimize treatment decisions. The test is available for clinical and research use and has coverage by Medicare across a broad range of indications. Signatera has been clinically validated across multiple cancer types and indications, with published evidence in more than 100 peer-reviewed papers.
About Natera
Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 250 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit www.natera.com.
Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in 'Risk Factors' in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Scam Summer: Experts Warn Price Caps May Fuel £100 Million in Ticket Fraud
LONDON--(BUSINESS WIRE)--With the UK heading into its biggest summer of live events in years, experts are warning that the Government's plans to cap the resale price of tickets could backfire - dramatically increasing fraud, pushing fans into the hands of scammers and triggering a financial backlash for both banks and consumers. Experts warn that price caps may fuel £100 million in ticket fraud. Share While the move to strengthen regulation is welcome, the proposal to restrict the price of resold tickets is raising serious concerns. In response to the Government's recent consultation on ticket resale regulation, which includes proposals to restrict the price of resold tickets, We Fight Fraud (WFF) - supported by one of the UK's leading fintechs, Revolut - is sounding the alarm: price caps won't protect fans - they'll expose them. Data from the National Fraud Intelligence Bureau, Action Fraud and the National Crime Agency shows that the cost of reported ticket fraud for England and Wales was £70 million last year. Yet this pales into insignificance with how much consumers would lose in the event of a mooted price cap being introduced. New figures from Bradshaw Advisory, backed by independent research from We Fight Fraud, suggest that number would quadruple as ticket resales migrate from the regulated secondary market to social media. This would mean consumers being hit in the pocket to the tune of £280 million a year – with £100 million of that falling in the peak summer months alone. Dr Nicola Harding, CEO of We Fight Fraud, a specialist unit made up of ex-police, intelligence officers, cyber experts, and financial crime investigators, said: 'Capping resale prices may sound fan-friendly - but in practice, it pushes buyers into unregulated, risky spaces where criminals operate freely. We've tested this market. We've seen what happens. Price caps don't stop fraud - they multiply it and we could see live event fans defrauded to the tune of £100 million this summer.' As part of its investigation, We Fight Fraud conducted a covert ticket-buying operation at a Premier League match in March between Liverpool and Southampton. The results were stark: Three out of four tickets purchased via social media in test cases were either fake or never arrived. Two out of five tickets were outright scams. Two others were obtained illegally via hijacked memberships. Buyers were asked to pay bogus 'name change' fees and transfer money to money mule accounts. All scams were orchestrated via social media platforms and encrypted messaging apps. 'These aren't opportunistic chancers,' said Harding. 'They're organised criminal networks exploiting fans who've been shut out of safe, legitimate resale routes. 'The more you limit legitimate access, the more you push desperate fans into the shadows - and that's exactly where scammers lie in wait.' While We Fight Fraud's research* focused on the UK, international data tells a worrying story. In Ireland and Victoria, Australia - where ticket resale caps are in place - fraud has surged. Bradshaw Advisory's research found that in Ireland, 13.6% of fans reported being scammed, over three times the UK's 3.8% rate. Independent research shows fraud has risen in step with these restrictions. Since October 2024, UK banks have been required to reimburse victims of Authorised Push Payment (APP) fraud, which includes most ticket scams. With resale restrictions forcing more buyers onto risky channels, the financial burden is now spreading from fans to banks - and eventually to the wider economy. Revolut saw ticket scams increase by 40% in the run-up to Taylor Swift concerts in London in August 2024. "We know that highly anticipated events, like concerts and sports matches, can become a target for unscrupulous criminals preying on enthusiastic fans,' said Dave Eborne, Head of Fraud Operations at Revolut. 'Especially with sought-after tickets, fraudsters leverage both the fear of missing out on a unique opportunity and a sense of urgency due to scarcity and high demand. The idea that a potential ticket could disappear quickly encourages people to act fast without thinking – but it's vital that consumers look for tell-tale warning signs before handing over their hard-earned cash. As Dr. Harding's research shows, banning or capping resale doesn't stop these scams; it simply provides another platform for them to thrive, costing fans and the wider economy through increased fraud. Smart, transparent regulation of the resale market, and robust consumer education on the warning signs of ticket scams, are the only real solutions to protect fans." For further information please contact contact@ or call us on +44(0)20 3633 0996 NOTES TO EDITORS About Revolut: Revolut is one of the UK's leading fintechs, helping people get more from their money. In 2015, Revolut launched in the UK offering money transfer and exchange. Today, more than 50 million customers around the world use dozens of Revolut's innovative products to make more than half a billion transactions a month. Across our personal and business accounts, we give customers more control over their finances and connect people seamlessly across the world. We Fight Fraud ( is a testing and research consultancy that specialises in identifying vulnerabilities related to financial crime. The independent research by WFF was commissioned by viagogo. Reinforcing We Fight Fraud's findings, Lloyds Bank recently issued a warning following a surge in scams linked to Oasis reunion tickets. Their analysis revealed that over two-thirds of all ticket scams now originate on social media, with Facebook responsible for 90% of those cases. Victims lost an average of £436, contributing to an estimated £2 million in total ticket scam losses over the past year. The scams typically involved convincing but fake listings, pressure to act quickly, and bogus charges like 'admin' or 'name change' fees - tactics that mirror those uncovered in We Fight Fraud's own investigations. REPORTING FRAUD: If you suspect fraud, report it to your bank and to Action Fraud at or if you prefer, on 0300 123 2040. If you're in Scotland, call Police Scotland on 101. About the data: Action fraud data from the NFIB dashboard shows the cost of ticket fraud for England and Wales is around £9.8m across the last 12 months. When you factor in that 86% of fraud goes unreported (Action Fraud and National Crime Agency), the more realistic figure is likely to be £70m across the last 12 months. If we regulate that with price caps, that figure will balloon to £280m (based on Bradshaw advisory research that shows level of fraud in markets with price caps is four times that of the UK). WFF's research at a Premier League football match investigation shows three in four tickets purchased were scams.
Yahoo
an hour ago
- Yahoo
Lazard Opens New UK Headquarters in Historic Manchester Square, W1
Lazard opens new, larger headquarters at 20 Manchester Square, extending the firm's near 150-year history in the UK Move reflects Lazard's continued commitment to the UK and London as one of the world's pre-eminent financial centres LONDON, June 02, 2025--(BUSINESS WIRE)--Lazard, Inc. (NYSE: LAZ) announced today that its new UK headquarters opened at 20 Manchester Square, housing both the firm's Financial Advisory and Asset Management businesses. The new, larger office reflects Lazard's commitment to London as one of the world's leading financial centres and the firm's continued growth in Europe. 20 Manchester Square will become part of Lazard's European footprint and one of its three main global offices, alongside New York and Paris. As a cornerstone of Lazard's international network, the new UK HQ extends the firm's long-standing presence in London which dates back to 1877. Cyrus Kapadia, Co-Head of European Investment Banking and CEO of UK Financial Advisory, said: "The move to 20 Manchester Square underscores our unwavering commitment to the UK and our deep-rooted heritage in London. We have been successfully growing our European teams and network to further support our clients across Europe and around the globe." Jeremy Taylor, CEO of Lazard UK Asset Management said, "20 Manchester Square is more than just a new office—it's a reflection of our values and vision. We are committed to delivering exceptional performance for our clients. This new UK headquarters embodies our dedication to innovation, collaboration, and thoughtful stewardship as we continue to best serve the needs of our clients." The new building offers modern office space and has been designed with an emphasis on innovation and sustainable standards of construction, technology and use. The space has renewable energy from solar panels on the roof and a rainwater harvesting system. The building's construction adhered to the UK Green Building Council framework for net-zero carbon emissions and recycled, long-life materials with reduced replaceability have been used across floors, walls and ceiling finishes, with water efficient taps, showers and fixtures in place throughout. 20 Manchester Square is situated next door to the Wallace Collection and Regent's Park, and the area is well known for its cultural landmarks and accessible transport links. Lazard UK is relocating from 50 Stratton Street, after over twenty years. ABOUT LAZARD Founded in 1848, Lazard is the preeminent financial advisory and asset management firm, with operations in North and South America, Europe, the Middle East, Asia, and Australia. Lazard provides advice on mergers and acquisitions, capital markets and capital solutions, restructuring and liability management, geopolitics, and other strategic matters, as well as asset management and investment solutions to institutions, corporations, governments, partnerships, family offices, and high net worth individuals. For more information, please visit and follow Lazard on LinkedIn. View source version on Contacts MEDIA CONTACTS Poppy Trowbridge, Financial Advisory+44 207 187 Zoe Butt, Asset Management+44 20 7448 INVESTOR CONTACT Alexandra Deignan+1 212 632 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
Lazard Opens New UK Headquarters in Historic Manchester Square, W1
LONDON--(BUSINESS WIRE)--Lazard, Inc. (NYSE: LAZ) announced today that its new UK headquarters opened at 20 Manchester Square, housing both the firm's Financial Advisory and Asset Management businesses. The new, larger office reflects Lazard's commitment to London as one of the world's leading financial centres and the firm's continued growth in Europe. 20 Manchester Square will become part of Lazard's European footprint and one of its three main global offices, alongside New York and Paris. As a cornerstone of Lazard's international network, the new UK HQ extends the firm's long-standing presence in London which dates back to 1877. Cyrus Kapadia, Co-Head of European Investment Banking and CEO of UK Financial Advisory, said: "The move to 20 Manchester Square underscores our unwavering commitment to the UK and our deep-rooted heritage in London. We have been successfully growing our European teams and network to further support our clients across Europe and around the globe." Jeremy Taylor, CEO of Lazard UK Asset Management said, '20 Manchester Square is more than just a new office—it's a reflection of our values and vision. We are committed to delivering exceptional performance for our clients. This new UK headquarters embodies our dedication to innovation, collaboration, and thoughtful stewardship as we continue to best serve the needs of our clients.' The new building offers modern office space and has been designed with an emphasis on innovation and sustainable standards of construction, technology and use. The space has renewable energy from solar panels on the roof and a rainwater harvesting system. The building's construction adhered to the UK Green Building Council framework for net-zero carbon emissions and recycled, long-life materials with reduced replaceability have been used across floors, walls and ceiling finishes, with water efficient taps, showers and fixtures in place throughout. 20 Manchester Square is situated next door to the Wallace Collection and Regent's Park, and the area is well known for its cultural landmarks and accessible transport links. Lazard UK is relocating from 50 Stratton Street, after over twenty years. ABOUT LAZARD Founded in 1848, Lazard is the preeminent financial advisory and asset management firm, with operations in North and South America, Europe, the Middle East, Asia, and Australia. Lazard provides advice on mergers and acquisitions, capital markets and capital solutions, restructuring and liability management, geopolitics, and other strategic matters, as well as asset management and investment solutions to institutions, corporations, governments, partnerships, family offices, and high net worth individuals. For more information, please visit and follow Lazard on LinkedIn.
